A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells
Amir Saeid Mahdavi, Nader Bagheri, Francesco M Marincola, Pegah Khosravian, Mahdi Ghatrehsamani · 2026
Read A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells by Amir Saeid Mahdavi, Nader Bagheri, Francesco M Marincola, Pegah Khosravian, Mahdi Ghatrehsamani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13151377.txt.
Description
Amir Saeid Mahdavi and co-authors tested a three part drug mix against breast cancer in mice for a 2026 paper. Breast cancer is the most common cancer in women, and waking up the immune system against it is a promising path. The mix pairs a TAK1 blocking drug with metformin, a metabolic drug, and an extract from shiitake mushroom mycelia. The target was a hard to treat form of the disease grown in mice.
Tumors in mice on the mix shrank in size and weight compared with controls. More killer T cells of a key active type entered the tumors. Levels of a tumor protein fell, and three genes tied to T cell exhaustion fell as well. Tests on breast cancer cell lines also showed the drugs lowered cell survival. The authors read the mix as a joint boost to anti tumor immunity.
Catalog record
| CREATOR | Amir Saeid Mahdavi, Nader Bagheri, Francesco M Marincola, Pegah Khosravian, Mahdi Ghatrehsamani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |